Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Merck’s KEYTRUDA Plus Chemotherapy Met Primary Endpoint of PFS as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Published 4 months ago
News Articles
More
Filters
Filters
Time & Location
Sources are mostly out of (0)
Bias Distribution
No sources with tracked biases.
See less detail